Developer docs
API playgroundTry for free, no card

Search company profiles

Brickell Biotech

Full company profile

uuid0005w4c

Namestring
Brickell Biotech
Websiteurl
brickellbio.com
Company typeenum
Private
Founded yearint
2009
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMiami, United States
HQ citystring
Miami
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
dermatology therapeutics, skin disease treatments, biopharmaceutical drugs, hyperhidrosis treatment, topical drug development
Industry1 code
1Dermatology Specialty Pharmaceuticals
CodeHLAIACALPrimaryYes
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Dermatology Pharmaceuticals
Social media profiles1 record
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Brickell Biotech is a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of prescription drug therapies for the treatment of skin diseases, including hyperhidrosis (excessive sweating). The company develops proprietary topical small-molecule therapeutics targeting dermatological conditions and has expanded its pipeline through corporate acquisitions such as Vical.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Drug therapies for skin diseases
CategoryPrescription Dermatology Therapeutics
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1AnaptysBio
TypeEmerging player
Description

AnaptysBio is a clinical-stage biotechnology company with a pipeline that includes dermatology indications (such as atopic dermatitis), making it a relevant emerging comparator in dermatology drug development.

2Hologic
TypeOthers
Description

Hologic participates in the broader women's health and dermatology/energy-based aesthetics markets referenced alongside Brickell's competitive set, with partial thematic overlap in dermatology devices/aesthetics.

3Incyte Corporation
TypeEmerging player
Description

Incyte has built a meaningful dermatology franchise (e.g., opzelura) and competes in adjacent inflammatory skin disease indications, providing a relevant emerging competitive reference for Brickell.

4Revance Therapeutics
TypeDirect peer
Description

Revance is a direct competitor in the hyperhidrosis and broader dermatology/aesthetics space, specifically developing therapeutic solutions that overlap with Brickell's focus on skin disease drug therapies.

5AbbVie
TypeBroad incumbent
Description

AbbVie is a broad incumbent in the hyperhidrosis space through Botox and Allergan Aesthetics, providing a well-funded competitive backdrop against which Brickell's small specialty pharma strategy must execute.

6Arcutis Biotherapeutics
TypeDirect peer
Description

Arcutis is a clinical and commercial-stage dermatology specialty pharmaceutical company developing topical treatments for skin conditions, sharing Brickell's therapeutic area and small-cap public profile.

7Dermavant Sciences
TypeDirect peer
Description

Dermavant is a dermatology-focused specialty pharma developing innovative topical therapies for skin diseases, directly comparable to Brickell's dermatology drug development focus.

8Galderma
TypeBroad incumbent
Description

Galderma is one of the world's largest dermatology-focused pharmaceutical companies, offering prescription, aesthetic, and consumer skin health products — a broad incumbent with significant overlap to Brickell's specialty.

9Verrica Pharmaceuticals
TypeDirect peer
Description

Verrica is a dermatology-focused specialty pharma developing treatments for skin diseases, including commercial and clinical-stage assets, making it a closely comparable peer in size and scope.

10Sol-Gel Technologies
TypeDirect peer
Description

Sol-Gel is a dermatology specialty pharmaceutical company developing topical branded generics and innovative therapies for skin diseases, comparable in scale and therapeutic focus to Brickell.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Brickell Biotech

Dermatology Pharmaceuticalsbrickellbio.com

Brickell Biotech firmographics

Firmographics
Name
Brickell Biotech
Website
https://brickellbio.com
Company type
Private
Founded year
2009
Headcount range
11–50 employees
Ownership category
akta.pro rank

Brickell Biotech industry classification

Industry
Product category
Dermatology Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro primary industry
Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

  • Dermatology therapeutics
  • Skin disease treatments
  • Biopharmaceutical drugs
  • Hyperhidrosis treatment
  • Topical drug development

Where Brickell Biotech is headquartered

Location

Headquarters

HQ city
Miami
HQ country
United States
HQ region
North America

Markets served

Brickell Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Brickell Biotech product offering

Product offering

Core offering

Brickell Biotech is a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of prescription drug therapies for the treatment of skin diseases, including hyperhidrosis (excessive sweating). The company develops proprietary topical small-molecule therapeutics targeting dermatological conditions and has expanded its pipeline through corporate acquisitions such as Vical.

Differentiator

Problem solved

Functional benefit

Products and services

  • Drug therapies for skin diseases

Companies that use Brickell Biotech

Customer profile

Ideal customer profiles1 record

Brickell Biotech technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Brickell Biotech partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Brickell Biotech competitors and assessment

Company assessment

Emerging players

  • AnaptysBio: AnaptysBio is a clinical-stage biotechnology company with a pipeline that includes dermatology indications (such as atopic dermatitis), making it a relevant emerging comparator in dermatology drug development.
  • Incyte Corporation: Incyte has built a meaningful dermatology franchise (e.g., opzelura) and competes in adjacent inflammatory skin disease indications, providing a relevant emerging competitive reference for Brickell.

Others

  • Hologic: Hologic participates in the broader women's health and dermatology/energy-based aesthetics markets referenced alongside Brickell's competitive set, with partial thematic overlap in dermatology devices/aesthetics.

Direct peers

  • Revance Therapeutics: Revance is a direct competitor in the hyperhidrosis and broader dermatology/aesthetics space, specifically developing therapeutic solutions that overlap with Brickell's focus on skin disease drug therapies.
  • Arcutis Biotherapeutics: Arcutis is a clinical and commercial-stage dermatology specialty pharmaceutical company developing topical treatments for skin conditions, sharing Brickell's therapeutic area and small-cap public profile.
  • Dermavant Sciences: Dermavant is a dermatology-focused specialty pharma developing innovative topical therapies for skin diseases, directly comparable to Brickell's dermatology drug development focus.
  • Verrica Pharmaceuticals: Verrica is a dermatology-focused specialty pharma developing treatments for skin diseases, including commercial and clinical-stage assets, making it a closely comparable peer in size and scope.
  • Sol-Gel Technologies: Sol-Gel is a dermatology specialty pharmaceutical company developing topical branded generics and innovative therapies for skin diseases, comparable in scale and therapeutic focus to Brickell.

Broad incumbents

  • AbbVie: AbbVie is a broad incumbent in the hyperhidrosis space through Botox and Allergan Aesthetics, providing a well-funded competitive backdrop against which Brickell's small specialty pharma strategy must execute.
  • Galderma: Galderma is one of the world's largest dermatology-focused pharmaceutical companies, offering prescription, aesthetic, and consumer skin health products — a broad incumbent with significant overlap to Brickell's specialty.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Brickell Biotech social profiles

Digital presence

Brickell Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Brickell Biotech leadership team

Management profile

Number of profiles

Profiles12 records

Brickell Biotech funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Brickell Biotech M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brickell Biotech

What does Brickell Biotech do?

Brickell Biotech is a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of prescription drug therapies for the treatment of skin diseases, including hyperhidrosis (excessive sweating). The company develops proprietary topical small-molecule therapeutics targeting dermatological conditions and has expanded its pipeline through corporate acquisitions such as Vical.

When was Brickell Biotech founded?

Brickell Biotech was founded in 2009. It employs 11 to 50 people.

Where is Brickell Biotech based?

Brickell Biotech is headquartered in Miami, United States, in the North America region.

Who are Brickell Biotech's main competitors?

Emerging players on record are AnaptysBio and Incyte Corporation. Hologic is listed as an others. Direct peers are Revance Therapeutics, Arcutis Biotherapeutics, Dermavant Sciences, Verrica Pharmaceuticals and Sol-Gel Technologies. Broad incumbents are AbbVie and Galderma.

Does Brickell Biotech have an API?

No public API is recorded for Brickell Biotech.

What industry is Brickell Biotech in?

Brickell Biotech's product category is Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireHealthcare Breakthroughs: IDRA, NMLSF, LMLLF, BBI; Life Sciences Leaders Report Latest Advances in Novel Therapeutics for Autism, Oncology, Autoimmune Diseases, and GlaucomaWall Street Reporter published CEO comments on four biotech companies: Idera's tilsotolimod trial stopped early with positive interim results, PharmaDrug advancing PD-001 for esophageal cancer with FDA orphan drug designation, Nova Mentis planning a Phase 2A psilocybin study for Fragile X, and Brickell Biotech targeting a mid-2022 NDA submission.GlobeNewswireBioMed Momentum: NMLSF, BBI, LMLLF, VERU; Life Sciences Leaders Report Latest Advances in New Drug Development for Autism, COVID-19, Oncology, and GlaucomaWall Street Reporter published CEO comments from Nova Mentis, Brickell Biotech, PharmaDrug, and Veru on new drug advances. Veru's sabizabulin showed a 55% reduction in deaths in a Phase 3 COVID-19 trial, while Brickell plans a mid-2022 NDA for sofpironium bromide. PharmaDrug and Nova Mentis also reported pipeline progress in oncology and autism.BenzingaThe Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, ConneThe article reports multiple biotech sector developments over a 24-hour period, including clinical trial results for Kezar Life Sciences (zetomipzomib failed to outperform placebo in Phase 2 for muscle inflammation), Connect Biopharma (CBP-307 missed primary endpoint in ulcerative colitis study, shares fell 33.5%), and Brickell Biotech (sold sofpironium bromide rights to Botanix Pharmaceuticals for up to $177 million, shares surged 30.3%). Regulatory advances included FDA approval of Phathom Pharmaceuticals' Voquezna for H. pylori infection, European approval of Novartis' Kymriah for follicular lymphoma, and FDA Fast Track designation for Aptose Biosciences' HM43239 in AML.GlobeNewswireHealthcare Breakthroughs: AGRX, NMLSF, BBI, LMLLF; BioMed Leaders Report Latest Advances in New Drug Development for Women’s Health, Autism, Glaucoma, and Cancer TherapeuticsWall Street Reporter published CEO comments from Brickell Biotech, Nova Mentis, Agile Therapeutics, and PharmaDrug on drug development advances. PharmaDrug's PD-001 received FDA Orphan Drug Designation for esophageal cancer, Agile Therapeutics reported 29% Twirla prescription growth, and Nova Mentis plans a Phase 2A psilocybin study for Fragile X.BenzingaBrickell Biotech, Carna Biosciences Ink Licensing Pact For STING inhibitorsBrickell Biotech Inc has entered into an exclusive licensing agreement with Carna Biosciences Inc to develop and commercialize Carna's portfolio of oral STING (Stimulator Interferon Genes) antagonists for treating autoimmune diseases. Under the terms, Brickell will make a $2.0 million upfront payment, up to $258.0 million in milestone payments, and pay tiered royalties ranging from mid-single digits up to 10% of net sales, while assuming responsibility for all future development activities and expenses. The announcement comes as Brickell's shares declined 3.65% to $0.25 during the trading session.BenzingaBrickell Biotech Aces Pivotal Sofpironium Trials In Patients With Excessive Underarm SweatingBrickell Biotech announced positive topline results from Phase 3 pivotal Cardigan I and II trials of sofpironium bromide gel for primary axillary hyperhidrosis, meeting primary efficacy endpoints in both studies. In Cardigan I, 49.3% of patients achieved at least a 2-point improvement in disease severity versus 29.4% for vehicle, while in Cardigan II the rates were 63.9% versus 47%, with the treatment being generally well-tolerated. The company plans to submit an FDA marketing application in mid-2022, with shares rising 10.2% in premarket trading following the announcement.PR NewswireThinking about buying stock in Camber Energy, Bit Digital, Brickell Biotech, Osmotica Pharmaceuticals, or SmileDirectClub?InvestorsObserver issued PriceWatch Alerts for stocks including Camber Energy, Bit Digital, Brickell Biotech, Osmotica Pharmaceuticals, and SmileDirectClub on October 7, 2021. The alerts utilize a proprietary scoring methodology evaluating short-term technical, long-term technical, and fundamental factors to determine investment suitability. This announcement serves as a routine market update regarding specific equity ratings.BenzingaWhy Brickell Biotech Shares Are Trading Lower TodayBrickell Biotech shares declined following the company's announcement of a bought deal offering for $7 million in common stock. The clinical-stage pharmaceutical firm, which is developing treatments for skin diseases, saw its stock drop 15.4% to $0.62 per share.BioSpaceBrickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 MillionBrickell Biotech has increased the size of its previously announced public offering to $7.0 million, raising capital by selling 11,290,323 shares at $0.62 per share due to investor demand. H.C. Wainwright & Co. is acting as the sole book-running manager for this firm commitment purchase, with closing expected around July 22, 2021. The company intends to utilize the net proceeds for research and development, including clinical trials, working capital, and general corporate purposes.PR NewswireThinking about buying stock in Vertex Energy, Exela Technologies, Bridgeline Digital, Verb Technology, or Brickell Biotech?The article provides a PriceWatch Alert for stocks from Vertex Energy, Exela Technologies, Bridgeline Digital, Verb Technology, and Brickell Biotech as of June 30, 2021. It highlights InvestorsObserver's proprietary scoring system that evaluates these stocks based on various technical and fundamental factors. Investors are encouraged to view the detailed ratings through provided links.